683P - Impact of age, bilirubin, and disease burden in unresectable pancreatic cancer patients receiving first-line chemotherapy: A population-based analysis
Date | 08 October 2016 |
Event | ESMO 2016 Congress |
Session | Poster Display |
Topics | Pancreatic Cancer |
Presenter | Ying Wang |
Citation | Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371 |
Authors |
Y. Wang1, P. Camateros2, W. Cheung1
|
Abstract
Background
FOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (NG), and gemcitabine (gem) are 3 systemic therapies that provide clinically meaningful benefit to patients with unresectable pancreatic cancer (UPC). Clinical trials have previously excluded patients with advanced age, elevated bilirubin, or locally advanced disease. Our aim was to examine whether age, bilirubin, and disease extent affected treatment outcomes.
Methods
Patients diagnosed with UPC who initiated palliative chemotherapy from August 2014 to August 2015 at any 1 of 5 cancer centers in British Columbia were identified from the provincial pharmacy. Clinical, pathological, treatment, and outcome characteristics were compared.
Results
150 patients were included: 53% men, 78% ECOG 0/1, and 71% with metastatic disease. Patients who received FFN and NG were younger (p
Conclusions
Receipt of FFN and NG portended a better prognosis than gem alone. In the absence of a randomized comparison of all 3 regimens, our population-based study revealed that the introduction of modified FFN and NG confers real world effectiveness for UPC patients regardless of age and bilirubin at presentation.
Clinical trial identification
N/A
Legal entity responsible for the study
Ying Wang
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.